Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation

Nuclear Medicine and Biology

Volumn 33, Issue 4, 2006, Pages 513-520

  Ogawa, Kazuma ^a,b   Mukai, Takahiro ^a,c   Arano, Yasushi ^d   Otaka, Akira ^a   Ueda, Masashi ^a   Uehara, Tomoya ^d   Magata, Yasuhiro ^e   Hashimoto, Kazuyuki ^f   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d CHIBA UNIVERSITY   (Japan)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JAPAN ATOMIC ENERGY AGENCY   (Japan)

Author keywords

Bisphosphonate; Bone; Monoaminemonoamidedithiols; Palliation; Rhenium 186

Indexed keywords

[N [2 [[3 (3,3 DIPHOSPHONOPROPYLCARBAMOYL)PROPYL] 2 THIOETHYLAMINO]ACETYL] 2 AMINOETHANETHIOLATE]OXORHENIUM RE 186; [N [2 [[4 [(4 HYDROXY 4,4 DIPHOSPHONOBUTYL)AMINO] 4 OXOBUTYL] 2 THIOETHYLAMINO]ACETYL] 2 AMINOETHANETHIOLATE]OXORHENIUM RE 186; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; GLYCINAMIDE; HYDROXYAPATITE; N 2 [4 [(4 HYDROXY 4,4 DIPHOSPHONOBUTYL)AMINO] 4 OXOBUTYL] N 1,N 2 BIS(2 TRITYLTHIOETHYL)GLYCINAMIDE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BONE PAIN; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG STRUCTURE; FEMUR; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PALLIATIVE THERAPY; RADIOACTIVITY; RADIOCHEMISTRY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DIPHOSPHONATES; DURAPATITE; FEMORAL NEOPLASMS; FEMUR; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED STRAINS; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; PAIN; PALLIATIVE CARE; TISSUE DISTRIBUTION;

EID: 33646547897     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2006.03.006     Document Type: Article

References (27)

1. Yoneda T., Sasaki A., and Mundy G.R. Osteolytic bone metastasis in breast cancer. Breast Cancer Res Treat 32 (1994) 73-84
2. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain 69 (1997) 1-18
3. Uppelschoten J.M., Wanders S.L., and de Jong J.M. Single-dose radiotherapy (6 Gy): palliation in painful bone metastases. Radiother Oncol 36 (1995) 198-202
4. Pandit-Taskar N., Batraki M., and Divgi C.R. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45 (2004) 1358-1365
5. McEwan A.J. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol 10 (2000) 103-114
6. Elder R.C., Yuan J., Helmer B., Pipes D., Deutsch K., and Deutsch E. Studies of the structure and composition of rhenium-1,1-hydroxyethylidenediphosphonate (HEDP) analogues of the radiotherapeutic agent (186)ReHEDP. Inorg Chem 36 (1997) 3055-3063
7. 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 41 (2000) 1689-1694
8. Limouris G.S., Shukla S.K., Condi-Paphiti A., Gennatas C., Kouvaris I., Vitoratos N., et al. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases. Anticancer Res 17 (1997) 1767-1772
9. O'Sullivan J.M., McCready V.R., Flux G., Norman A.R., Buffa F.M., Chittenden S., et al. High activity rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer 86 (2002) 1715-1720
10. De Winter F., Brans B., Van De Wiele C., and Dierckx R.A. Visualization of the stomach on rhenium-186 HEDP imaging after therapy for metastasized prostate carcinoma. Clin Nucl Med 24 (1999) 898-899
11. de Klerk J.M., van Dijk A., van het Schip A.D., Zonnenberg B.A., and van Rijk P.P. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 33 (1992) 646-651
12. 186Re complex of 1-hydroxyethylidene-1,1-diphosphonate for treatment of painful osseous metastases. Radioisotopes 44 (1995) 514-522
13. Ogawa K., Mukai T., Arano Y., Hanaoka H., Hashimoto K., Nishimura H., et al. Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Label Cmpd Radiopharm 47 (2004) 753-761
14. Meyer J.L., and Nancollas G.H. The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calcif Tissue Res 13 (1973) 295-303
15. van Beek E., Hoekstra M., van de Ruit M., Lowik C., and Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 9 (1994) 1875-1882
16. 188Re generator. Radiochemistry 42 (2000) 551-554
17. Kieczykowski GR. New process for preparing an antihypercalcemic agent. UK Patent GB 2248061A, 1992.
18. 6 conjugation. J Bone Miner Res 15 (2000) 936-943
19. Fujisawa R., and Kuboki Y. Preferential adsorption of dentin and bone acidic proteins on the (100) face of hydroxyapatite crystals. Biochim Biophys Acta 1075 (1991) 56-60
20. 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study. Nucl Med Commun 18 (1997) 582-588
21. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 19 (1998) 80-100
22. Rodan G.A., and Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 97 (1996) 2692-2696
23. 2O. Implications for the chemistry of technetium-99m-diphosphonate skeletal imaging agents. Inorg Chem 22 (1983) 1332-1338
24. Subramanian G., McAfee J.G., Thomas F.D., Feld T.A., Zapf-Longo C., and Palladino E. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate. Radiology 149 (1983) 823-828
25. Fogelman I., Pearson D.W., Bessent R.G., Tofe A.J., and Francis M.D. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication. J Nucl Med 22 (1981) 880-883
26. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., and Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 28 (1987) 495-504
27. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B 14 (1987) 223-232